EP1028717B1 - Unsubstituted polydiallylamine for treating hypercholesterolemia - Google Patents

Unsubstituted polydiallylamine for treating hypercholesterolemia Download PDF

Info

Publication number
EP1028717B1
EP1028717B1 EP98957370A EP98957370A EP1028717B1 EP 1028717 B1 EP1028717 B1 EP 1028717B1 EP 98957370 A EP98957370 A EP 98957370A EP 98957370 A EP98957370 A EP 98957370A EP 1028717 B1 EP1028717 B1 EP 1028717B1
Authority
EP
European Patent Office
Prior art keywords
polymer
solution
polydiallylamine
hours
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP98957370A
Other languages
German (de)
French (fr)
Other versions
EP1028717A2 (en
Inventor
Chad Cori Huval
Stephen Randall Holmes-Farley
John S. Petersen
Pradeep K. Dhal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Geltex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geltex Pharmaceuticals Inc filed Critical Geltex Pharmaceuticals Inc
Publication of EP1028717A2 publication Critical patent/EP1028717A2/en
Application granted granted Critical
Publication of EP1028717B1 publication Critical patent/EP1028717B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • One method of reducing the amount of bile acids that are reabsorbed and, thus, reducing serum cholesterol is the oral administration of compounds that sequester the bile acids and cannot themselves be absorbed.
  • the sequestered bile acids are excreted.
  • US-A-5607669 also discloses an amine polymer as a bile acid sequestrant.
  • the invention relates to the unexpected discovery that a new class of ion exchange resins have improved bile salt sequestration properties.
  • the polymers, or resins, employed in the invention comprise non-absorbable, and optionally cross-linked polydiallylamines.
  • the polydiallylamines of the invention are characterized by one or more monomeric units of the formulae; or a combination thereof and salts thereof.
  • the polymer can be characterized by the substantial absence of one or more alkylated amine monomers and/or the substantial absence of one or more trialkylammonium alkyl groups.
  • the polymer is crosslinked by means of a multifunctional crosslinking agent.
  • the polymer can also be characterized as being linear or branched.
  • the invention provides an effective treatment for removing bile salts from a patient (and thereby reducing the patient's cholesterol level).
  • the invention also provides for the use of the polymers described herein in therapy or for the manufacture of a medicament for the treatment of hypercholesterolemia or for bile acid sequestration.
  • the invention discloses the use of a polymer comprising a polydiallylamine polymer and salts thereof, wherein said polydiallylamine polymer is substantially free of alkylated amine monomers for the manufacture of a medicament for removing bile salts from a patient.
  • the term "therapeutically effective amount” refers to an amount which is sufficient to remove a significant quantity of bile acids from the patient and, thus, to lower the serum cholesterol level of the patient.
  • the patient can be an animal, for example, a mammal, or a human.
  • the polymer is rendered water-insoluble by branching and/or crosslinking.
  • the cross-linking agent can be characterized by functional groups which react with the amino group of the monomer.
  • the crosslinking group can be characterized by two or more vinyl groups which undergo free radical polymerization with the amine monomer.
  • Suitable multifunctional co-monomers include triallylamine, tetraallyleammonium salts, bis(diallylamine)s (such as alkylene bis(diallylamine)s), diacrylates, triacrylates and tetraacrylates, dimethacrylates, diacrylamides, diallylacrylamide and di(methacrylamides).
  • Other suitable multifunctional monomers include polyvinylarenes, such as divinylbenzene.
  • the polymer can alternatively be crosslinked by bridging units which link amino groups on adjacent polymer strands.
  • Suitable bridging units include straight chain or branched, substituted or unsubstituted alkylene groups, diacylalkylene groups, diacylarene groups and alkylene bis(carbamoyl) groups.
  • Suitable bridging units include -(CH 2 ) n -, wherein n is an integer from about 2 to about 20; -CH 2 -CH(OH)-CH 2 -; -C(O)CH 2 CH 2 C(O)-; -CH 2 -CH(OH)-O-(CH 2 ) n -O-CH(OH)-CH 2 -, wherein n is 2 to 4; -C(O)-(C 6 H 2 (COOH) 2 )-C(O)- and -C(O)NH(CH 2 ) p NHC(O)-, wherein p is an integer from 2 to 20.
  • crosslinking agents examples include acryloyl chloride, epichlorohydrin, butanedioldiglycidyl ether, ethanedioldiglycidyl ether, and dimethyl succinate.
  • the level of crosslinking makes the polymers insoluble and substantially resistant to absorption and degradation, thereby limiting the activity of the polymer to the gastrointestinal tract.
  • the compositions are non-systemic in their activity and will lead to reduced side-effects in the patient.
  • the cross-linking agent is present in an amount from 0.5-50% (more preferably 0.5-30% and most preferably 2-20%) by weight, based upon total weight of monomer plus crosslinking agent.
  • polymers of use in the present method are, preferably, of a molecular weight which enables them to reach and remain in the gastrointestinal tract for a sufficient period of time to bind a significant amount of one or more bile acids. These polymers should, thus, be of sufficiently high molecular weight to resist, partially or completely, absorption from the gastrointestinal tract into other regions of the body. The resulting polymer/bile salt complex should then be excreted from the body. Suitable linear (non-crosslinked) polymers have molecular weights which range from 2,000 Daltons to 500,000 Daltons, preferably from 5,000 Daltons to 150,000 Daltons. Crosslinked polymers, however, are not generally characterized by molecular weight. The crosslinked polymers discussed herein should be sufficiently crosslinked to resist adsorption from the gastrointestinal tract.
  • the polymer can be administered in the form of a salt, or as a partial salt.
  • salt it is meant that the nitrogen groups in all or some of the repeat units are protonated to create a positively charged nitrogen atom associated with a negatively charged counterion.
  • the polymer can be administered either in hydrated or dehydrated form, and can be flavored or added to a food or drink, if desired, to enhance patient acceptability. Additional ingredients such as other bile acid sequestrants, drugs for treating hypercholesterolemia, atherosclerosis or other related indications, or inert ingredients, such as artificial coloring agents can be added as well.
  • suitable forms for administration include pills, tablets, capsules, and powders (e.g., for sprinkling on food).
  • the pill, tablet, capsule, or powder can be coated with a substance capable of protecting the composition from disintegration in the esophagus but will allow disintegration of the composition in the stomach and mixing with food to pass into the patient's small intestine.
  • the polymer can be administered alone or in combination with a pharmaceutically acceptable carrier, diluent or excipient substance, such as a solid, liquid or semi-solid material.
  • Suitable carriers, diluents and excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, alginates, tragacanth, gelatin, calcium silicate, cellulose e.g., magnesium carbonate or a phospholipid with which the polymer can form a micelle.
  • Polymers of use in the present method can be prepared using techniques known in the art of polymer synthesis (see for example, Shalaby et al ., ed., WaterSoluble Polymers, American Chemical Society, Washington D.C. (1991)).
  • the appropriate monomer(s) can be polymerized by methods known in the art, for example, via a free radical addition process.
  • the polymerization mixture includes a free-radical initiator, such as a free radical initiator selected from among those which are well known in the art of polymer chemistry.
  • Suitable free-radical initiators include azobis(isobutyronitrile), azobis(4-cyanovaleric acid), azobis(amidinopropane) dihydrochloride, potassium persulfate, ammonium persulfate and potassium hydrogen persulfate.
  • the free radical initiator is preferably present in the reaction mixture in an amount ranging from 0.1 mole percent to 5 mole percent relative to the monomer.
  • the polymer can be crosslinked, for example, by including a multifunctional co-monomer as the crosslinking agent in the reaction mixture.
  • a multifunctional co-monomer can be incorporated into two or more growing polymer chains, thereby crosslinking the chains.
  • Suitable multifunctional co-monomers include those discussed above.
  • Suitable crosslinking agents of this type include compounds having two or more groups selected from among acyl-X, epoxide, and alkyl-X, wherein X is a suitable leaving group, such as a halo, tosyl, mesyl, acyl or glycidyl group.
  • X is a suitable leaving group, such as a halo, tosyl, mesyl, acyl or glycidyl group.
  • Examples of such compounds include epichlorohydrin, succinyl dichloride, butanedioldiglycidyl ether, ethanedioldiglycidyl ether, pyromellitic dianhydride and dihaloalkanes.
  • the crosslinking agent can also be an ⁇ , ⁇ -alkylene diisocyanate, for example OCN(CH 2 ) p NCO, wherein p is an integer from 2 to 20.
  • the polymer can also be crosslinked using a crosslinking agent which incorporates one functional group which incorporates into the polymerizing chain and a second functional group which can react with amine groups in a second polymer chain.
  • a crosslinking agent which incorporates one functional group which incorporates into the polymerizing chain and a second functional group which can react with amine groups in a second polymer chain. Examples include glycidyl methacrylate, glycidyl acrylate, acryloyl chloride, methacryloyl chloride, 3-bromopropylacrylate, 3-bromopropylmethyl-diallylammonium chloride, and 3-chloropropyldiallylamine.
  • Concentrated hydrochloric acid (507.0 g; 37%) was charged to a 5L, 3-neck round bottomed flask and agitated with a mechanical stirrer. The flask was cooled to ⁇ 5°C with an ice bath. Diallylamine (635.0 ml) was added dropwise to the stirring hydrochloric acid over a three hour period using an addition funnel capped with a pierced rubber septum. The stirring solution temperature was maintained at ⁇ 10°C. After the addition was completed, the ice bath was removed and the mixture was allowed to warm to room temperature. Concentrated hydrochloric acid (7.3 g) was added to the solution. Water (368.7 g) was added to the solution and it was allowed to sit overnight.
  • 2,2'-Azobis[2-amidinopropane]dihydrochloride (6.87 g) was added as a 20% aqueous solution. The solution was stirred and heated for another 16 hours, then cooled to room temperature.
  • a solution of 39.3 g of an aqueous solution (68 wt%) of diallylammonium hydrochloride, 5.3 g of an aqueous solution (73 wt%)of triallylamine hydrochloride and 0.9 g of 2,2'-azobis(2-amidinopropane)dihydrochloride was bubbled with a slow stream of nitrogen for 30 minutes. While stirring, this reaction mixture was added to a solution of 7 g of polyvinylacetate in 300 mL of toluene. The resulting mixture was stirred at room temperature for 45 minutes under nitrogen atmosphere. While stirring, the temperature of the reaction mixture was raised to 60 C and was held at this temperature for 24 hours.
  • the reaction mixture was allowed to cool to room temperature and the polymer particles were collected by filtration. While in the funnel, the filtered particles were successively washed with 300 mL of toluene and 500 mL of methanol. The polymer particles were suspended in 500 mL of methanol, stirred for 50 minutes, and filtered. Subsequently, the particles were suspended in 400 mL of deionized water, stirred for 30 minutes and filtered, The filtered particles were dried at 60 C for 24 hr to yield 15 g of the polymer.
  • Example 1 The polymer solution of Example 1 was crosslinked at 30 mole % as follows:
  • Epichlorohydrin (31.61 mL) was added to 900.0 g of the neutralized polymer solution in a glass beaker, agitated with a magnetic stirrer and covered with polyvinyl film. The gel was allowed to cure for 22 hours. The solid gel was then ground using a Kitchen Aid grinder. The ground polymer was washed in a static bed manner using a large plastic Buchner funnel lined with filter paper. A second piece of filter paper, perforated with holes, was placed on top of the polymer cake to prevent disturbing the cake when adding wash water. Fresh deionized H 2 O(14 L) - was added to the top of the cake and drained under vacuum. The washed polymer was then transferred to glass drying trays and dried in a 60°C forced air oven for several days. The final dry weight was 176.2 g.
  • Example 3 Using the same procedure as in Example 3, the neutralized polymer solution was crosslinked at 20 mole %. Epichlorohydrin (21.07 mL) was added to 900.0 g of the neutralized polymer solution. The final dry weight was 163.3 g.
  • Example 3 Using the same procedure as in Example 3, the neutralized polymer solution was crosslinked at 10 mole %. Epichlorohydrin (10.54 mL) was added to 900.0 g of the neutralized polymer solution. The final dry weight was 164.2 g.
  • Example 3 Using the same procedure as in Example 3, the neutralized polymer solution was crosslinked at 4.5 mole %. Epichlorohydrin (4.74 mL) was added to 900.0 g of the neutralized polymer solution. The final dry weight was 176.2 g.
  • Example 10 Copolymer of Diallylamine, a Functionalized Acrylic Ester and an Acrylic Ester Cross-linking Monomer
  • Example 11 Copolymer of Diallylamine, a Functionalized Acrylic Ester and an Acrylic Ester Cross-linking Monomer
  • diallylammonium chloride 22.06 g of a 68% aqueous solution
  • tetrahydrofurfuryl methacrylate (18.72 g)
  • ethyleneglycol dimethacrylate (4.36 g)
  • 2,2'-azobis(2-amidinopropane) dihydrochloride (2.03 g of an 18.8% aqueous solution) was heated at 65°C under a nitrogen atmosphere for 24 hours.
  • the resulting material was suspended in methanol (300 mL), stirred 15 minutes and filtered. This methanol wash and filtration was repeated twice more.
  • the polymer was similarly washed three times with water (500mL).
  • the material was suspended in water (500 mL) and this mixture was acidified with concentrated HCl to pH 2.0. Filtration, and drying at 60°C in a forced-air oven gave 19.9 g of a solid.

Abstract

A method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of a non-absorbable polydiallylamine polymers.

Description

    BACKGROUND OF THE INVENTION
  • Reabsorption of bile acids from the intestine conserves lipoprotein cholesterol in the bloodstream. Conversely, blood cholesterol levels can be diminished by reducing reabsorption of bile acids.
  • One method of reducing the amount of bile acids that are reabsorbed and, thus, reducing serum cholesterol is the oral administration of compounds that sequester the bile acids and cannot themselves be absorbed. The sequestered bile acids are excreted.
  • Compounds which have been suggested for bile acid sequestration include various ion exchange polymers. One such polymer is cholestyramine, a copolymer of divinylbenzene and trimethylammoniummethyl styrene. It has been long recognized that this polymer is unpalatable, gritty, and constipating. More recently; various polymers have been suggested which are characterized by hydrophobic substituents and quaternary ammonium radicals substituted upon an amine polymer backbone (Ahlers, et al. U.S. Patent 5,428,112 and 5,430,110 and McTaggart, et al., U.S. Patent 5,462,730). In some cases, these polymers have had disappointing efficacy and require complex processes for their manufacture
  • US-A-5607669 also discloses an amine polymer as a bile acid sequestrant.
  • Thus, there is still a need to discover superior bile acid sequestrants.
  • SUMMARY OF THE INVENTION
  • The invention relates to the unexpected discovery that a new class of ion exchange resins have improved bile salt sequestration properties. The polymers, or resins, employed in the invention comprise non-absorbable, and optionally cross-linked polydiallylamines. The polydiallylamines of the invention are characterized by one or more monomeric units of the formulae;
    Figure 00020001
    or a combination thereof and salts thereof. The polymer can be characterized by the substantial absence of one or more alkylated amine monomers and/or the substantial absence of one or more trialkylammonium alkyl groups. In preferred embodiments, the polymer is crosslinked by means of a multifunctional crosslinking agent. The polymer can also be characterized as being linear or branched.
  • The invention provides an effective treatment for removing bile salts from a patient (and thereby reducing the patient's cholesterol level). The invention also provides for the use of the polymers described herein in therapy or for the manufacture of a medicament for the treatment of hypercholesterolemia or for bile acid sequestration.
  • Other features and advantages will be apparent from the following description of the preferred embodiments thereof and from the claims.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The features and other details of the invention will now be more particularly described and pointed out in the claims. It will be understood that the particular embodiments of the invention are shown by way of illustration and not as limitations of the invention. The principal features of the invention can be employed in various embodiments without departing from the scope of the present invention.
  • The invention discloses the use of a polymer comprising a polydiallylamine polymer and salts thereof, wherein said polydiallylamine polymer is substantially free of alkylated amine monomers for the manufacture of a medicament for removing bile salts from a patient.
  • As used herein, the term "therapeutically effective amount" refers to an amount which is sufficient to remove a significant quantity of bile acids from the patient and, thus, to lower the serum cholesterol level of the patient. The patient can be an animal, for example, a mammal, or a human.
  • As described above, the polymers employed in the invention comprise non-absorbable, optionally cross-linked polydiallylamines characterized by the formula above. Importantly, the polymers can be characterized by the substantial absence of substituted or unsubstituted alkyl substituents on the amino group of the monomer, such as obtained in the alkylation of an amine polymer. That is, the polymer can be characterized in that the polymer is substantially free of alkylated amine monomers.
  • The polymer can be a homopolymer or a copolymer. Where copolymers are manufactured with a diallylamine monomer, the comonomers are preferably inert, non-toxic and/or possess bile acid sequestration properties. Suitable examples of additional comonomers include substituted and unsubstituted acrylate, substituted and unsubstituted acrylamide, substituted and unsubstituted methacrylate, substituted and unsubstituted methacrylamide, allylamine, triallylamine, allyl alcohol, substituted and unsubstituted vinyl amine and substituted and unsubstituted vinyl alcohol. In one embodiment, the additional monomer is sulfur dioxide. Preferably, the monomers are aliphatic. Most preferably, the polymer is a homopolymer, i.e. a homopolydiallylamine.
  • Preferably, the polymer is rendered water-insoluble by branching and/or crosslinking. The cross-linking agent can be characterized by functional groups which react with the amino group of the monomer. Alternatively, the crosslinking group can be characterized by two or more vinyl groups which undergo free radical polymerization with the amine monomer. Suitable multifunctional co-monomers include triallylamine, tetraallyleammonium salts, bis(diallylamine)s (such as alkylene bis(diallylamine)s), diacrylates, triacrylates and tetraacrylates, dimethacrylates, diacrylamides, diallylacrylamide and di(methacrylamides). Specific examples include ethylene bis(diallylamine), hexamethylene bis(diallylamine), ethylene glycol diacrylate, propylene glycol diacrylate, butylene glycol diacrylate, ethylene glycol dimethacrylate, butylene glycol dimethacrylate, methylene bis(methacrylamide), ethylene bis(acrylamide), ethylene bis(methacrylamide), ethylidene bis(acrylamide), ethylidene bis(methacrylamide), pentaerythritol tetraacrylate, trimethylolpropane triacrylate, bisphenol A dimethacrylate, and bisphenol A diacrylate. Other suitable multifunctional monomers include polyvinylarenes, such as divinylbenzene.
  • The polymer can alternatively be crosslinked by bridging units which link amino groups on adjacent polymer strands. Suitable bridging units include straight chain or branched, substituted or unsubstituted alkylene groups, diacylalkylene groups, diacylarene groups and alkylene bis(carbamoyl) groups. Examples of suitable bridging units include -(CH2)n-, wherein n is an integer from about 2 to about 20; -CH2-CH(OH)-CH2-; -C(O)CH2CH2C(O)-; -CH2-CH(OH)-O-(CH2)n-O-CH(OH)-CH2-, wherein n is 2 to 4; -C(O)-(C6H2(COOH)2)-C(O)- and -C(O)NH(CH2)pNHC(O)-, wherein p is an integer from 2 to 20.
  • Examples of suitable crosslinking agents include acryloyl chloride, epichlorohydrin, butanedioldiglycidyl ether, ethanedioldiglycidyl ether, and dimethyl succinate.
  • A preferred crosslinking agent is epichlorohydrin because of its high availability and low cost. Epichlorohydrin is also advantageous because of it's low molecular weight and hydrophilic nature, increasing the water-swellability of the polyamine.
  • The level of crosslinking makes the polymers insoluble and substantially resistant to absorption and degradation, thereby limiting the activity of the polymer to the gastrointestinal tract. Thus, the compositions are non-systemic in their activity and will lead to reduced side-effects in the patient. Typically, the cross-linking agent is present in an amount from 0.5-50% (more preferably 0.5-30% and most preferably 2-20%) by weight, based upon total weight of monomer plus crosslinking agent.
  • When used in a non-crosslinked form, polymers of use in the present method are, preferably, of a molecular weight which enables them to reach and remain in the gastrointestinal tract for a sufficient period of time to bind a significant amount of one or more bile acids. These polymers should, thus, be of sufficiently high molecular weight to resist, partially or completely, absorption from the gastrointestinal tract into other regions of the body. The resulting polymer/bile salt complex should then be excreted from the body. Suitable linear (non-crosslinked) polymers have molecular weights which range from 2,000 Daltons to 500,000 Daltons, preferably from 5,000 Daltons to 150,000 Daltons. Crosslinked polymers, however, are not generally characterized by molecular weight. The crosslinked polymers discussed herein should be sufficiently crosslinked to resist adsorption from the gastrointestinal tract.
  • As described above the polymer can be administered in the form of a salt, or as a partial salt. By "salt" it is meant that the nitrogen groups in all or some of the repeat units are protonated to create a positively charged nitrogen atom associated with a negatively charged counterion.
  • The anionic counterions can be selected to minimize adverse effects on the patient, as is more particularly described below. Examples of suitable counterions include Cl-, Br-, CH3OSO3 -, HSO4 -, SO4 2-, nitrate, HCO3 -,CO3 2--acetate, lactate, phosphate, hydrophosphate, methanesulfonate, fumarate, malate, pyruvate, malonate, benzoate, glucuronate, oxalate, acetylglycinate, succinate, propionate, butyrate, ascorbate, citrate, tartrate, maleate, folate, an amino acid derivative, a nucleotide, a lipid, or a phospholipid. The counterions can be the same as, or different from, each other. For example, the reaction product can contain two different types of counterions.
  • The polymers according to the invention can be administered orally to a patient in a dosage of 1 mg/kg/day to 10 g/kg/day, preferably between
  • 1 mg/kg/day to 200 mg/kg/day; the particular dosage will depend on the individual patient (e.g., the patient's weight and the extent of bile salt removal required). The polymer can be administered either in hydrated or dehydrated form, and can be flavored or added to a food or drink, if desired, to enhance patient acceptability. Additional ingredients such as other bile acid sequestrants, drugs for treating hypercholesterolemia, atherosclerosis or other related indications, or inert ingredients, such as artificial coloring agents can be added as well.
  • Examples of suitable forms for administration include pills, tablets, capsules, and powders (e.g., for sprinkling on food). The pill, tablet, capsule, or powder can be coated with a substance capable of protecting the composition from disintegration in the esophagus but will allow disintegration of the composition in the stomach and mixing with food to pass into the patient's small intestine. The polymer can be administered alone or in combination with a pharmaceutically acceptable carrier, diluent or excipient substance, such as a solid, liquid or semi-solid material. Examples of suitable carriers, diluents and excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, alginates, tragacanth, gelatin, calcium silicate, cellulose e.g., magnesium carbonate or a phospholipid with which the polymer can form a micelle.
  • Polymers of use in the present method can be prepared using techniques known in the art of polymer synthesis (see for example, Shalaby et al., ed., WaterSoluble Polymers, American Chemical Society, Washington D.C. (1991)). For example, the appropriate monomer(s) can be polymerized by methods known in the art, for example, via a free radical addition process. In this case the polymerization mixture includes a free-radical initiator, such as a free radical initiator selected from among those which are well known in the art of polymer chemistry. Suitable free-radical initiators include azobis(isobutyronitrile), azobis(4-cyanovaleric acid), azobis(amidinopropane) dihydrochloride, potassium persulfate, ammonium persulfate and potassium hydrogen persulfate. The free radical initiator is preferably present in the reaction mixture in an amount ranging from 0.1 mole percent to 5 mole percent relative to the monomer.
  • The polymer can be crosslinked, for example, by including a multifunctional co-monomer as the crosslinking agent in the reaction mixture. A multifunctional co-monomer can be incorporated into two or more growing polymer chains, thereby crosslinking the chains. Suitable multifunctional co-monomers include those discussed above.
  • The polymers can also be crosslinked subsequent to polymerization by reacting the polymer with one or more crosslinking agents having two or more functional groups, such as electrophilic groups, which react with amine groups to form a covalent bond. Crosslinking in this case can occur, for example, via nucleophilic attack of the polymer amino groups on the electrophilic groups. This results in the formation of a bridging unit which links two or more amino nitrogen atoms from different polymer strands. Suitable crosslinking agents of this type include compounds having two or more groups selected from among acyl-X, epoxide, and alkyl-X, wherein X is a suitable leaving group, such as a halo, tosyl, mesyl, acyl or glycidyl group. Examples of such compounds include epichlorohydrin, succinyl dichloride, butanedioldiglycidyl ether, ethanedioldiglycidyl ether, pyromellitic dianhydride and dihaloalkanes. The crosslinking agent can also be an α,ω-alkylene diisocyanate, for example OCN(CH2)pNCO, wherein p is an integer from 2 to 20.
  • The polymer can also be crosslinked using a crosslinking agent which incorporates one functional group which incorporates into the polymerizing chain and a second functional group which can react with amine groups in a second polymer chain. Examples include glycidyl methacrylate, glycidyl acrylate, acryloyl chloride, methacryloyl chloride, 3-bromopropylacrylate, 3-bromopropylmethyl-diallylammonium chloride, and 3-chloropropyldiallylamine.
  • The invention will now be described more specifically by the examples.
  • Example 1 - Preparation of Poly(diallylammonium chloride)
  • Concentrated hydrochloric acid (507.0 g; 37%) was charged to a 5L, 3-neck round bottomed flask and agitated with a mechanical stirrer. The flask was cooled to <5°C with an ice bath. Diallylamine (635.0 ml) was added dropwise to the stirring hydrochloric acid over a three hour period using an addition funnel capped with a pierced rubber septum. The stirring solution temperature was maintained at <10°C. After the addition was completed, the ice bath was removed and the mixture was allowed to warm to room temperature. Concentrated hydrochloric acid (7.3 g) was added to the solution. Water (368.7 g) was added to the solution and it was allowed to sit overnight.
  • The stirring solution was purged with nitrogen gas for 30 minutes at room temperature. 2,2'-Azobis[2-amidinopropane]dihydrochloride (6.87 g) was added as 34.4 g of a 20% aqueous solution. The solution was heated to 60°-80°C for six and one-half hours. 2,2'-Azobis[2-amidinopropane] dihydrochloride (6.87g) was added as a 20% aqueous solution. The solution was stirred and heated overnight (16 hours).
  • 2,2'-Azobis[2-amidinopropane]dihydrochloride (6.87 g) was added as a 20% aqueous solution. The solution was stirred and heated for another 16 hours, then cooled to room temperature.
  • Sodium hydroxide (53.8 g) was dissolved in H2O (2156 mL). The polydiallylamine·HCl solution was then added to the sodium hydroxide solution and agitated with a mechanical stirrer until dissolved. Concentrated hydrochloric acid (49.8 g; 37%) was added.
  • Example 2 - Synthesis of polydiallylamine
  • A solution of 39.3 g of an aqueous solution (68 wt%) of diallylammonium hydrochloride, 5.3 g of an aqueous solution (73 wt%)of triallylamine hydrochloride and 0.9 g of 2,2'-azobis(2-amidinopropane)dihydrochloride was bubbled with a slow stream of nitrogen for 30 minutes. While stirring, this reaction mixture was added to a solution of 7 g of polyvinylacetate in 300 mL of toluene. The resulting mixture was stirred at room temperature for 45 minutes under nitrogen atmosphere. While stirring, the temperature of the reaction mixture was raised to 60 C and was held at this temperature for 24 hours. The reaction mixture was allowed to cool to room temperature and the polymer particles were collected by filtration. While in the funnel, the filtered particles were successively washed with 300 mL of toluene and 500 mL of methanol. The polymer particles were suspended in 500 mL of methanol, stirred for 50 minutes, and filtered. Subsequently, the particles were suspended in 400 mL of deionized water, stirred for 30 minutes and filtered, The filtered particles were dried at 60 C for 24 hr to yield 15 g of the polymer.
  • Example 3 - Cross-linked Polydiallylamine
  • The polymer solution of Example 1 was crosslinked at 30 mole % as follows:
  • Epichlorohydrin (31.61 mL) was added to 900.0 g of the neutralized polymer solution in a glass beaker, agitated with a magnetic stirrer and covered with polyvinyl film. The gel was allowed to cure for 22 hours. The solid gel was then ground using a Kitchen Aid grinder. The ground polymer was washed in a static bed manner using a large plastic Buchner funnel lined with filter paper. A second piece of filter paper, perforated with holes, was placed on top of the polymer cake to prevent disturbing the cake when adding wash water. Fresh deionized H2O(14 L)- was added to the top of the cake and drained under vacuum. The washed polymer was then transferred to glass drying trays and dried in a 60°C forced air oven for several days. The final dry weight was 176.2 g.
  • Example 4 - Crosslinked Polydiallylamine
  • Using the same procedure as in Example 3, the neutralized polymer solution was crosslinked at 20 mole %. Epichlorohydrin (21.07 mL) was added to 900.0 g of the neutralized polymer solution. The final dry weight was 163.3 g.
  • Example 5 - Crosslinked Polydiallylamine
  • Using the same procedure as in Example 3, the neutralized polymer solution was crosslinked at 10 mole %. Epichlorohydrin (10.54 mL) was added to 900.0 g of the neutralized polymer solution. The final dry weight was 164.2 g.
  • Example 6 - Crosslinked Polydiallylamine
  • Using the same procedure as in Example 3, the neutralized polymer solution was crosslinked at 4.5 mole %. Epichlorohydrin (4.74 mL) was added to 900.0 g of the neutralized polymer solution. The final dry weight was 176.2 g.
  • Example 7 - Copolymer of Diallylamine and Methylenebisacrylamide
  • A solution of diallylammoniuim chloride (73.53 g of 68% aqueous solution), methylenebisacrylamide (2.93 g, 0.019 mol), 2,2'-azobis(2-amidinopropane) dihydrochloride (V50) (0.5 g) and water (27 mL) was heated at 70°C under a nitrogen atmosphere. Water (100 mL) was added after 15 minutes of reaction. An additional 0.5 g of V50 was added after 3 hours and again after 4 more hours. After keeping the reaction at 70 C for a total of 72 hr, it was cooled to room temperature. The resulting material was filtered and washed with 2 M NaCI (400 mL), and filtered and washed with water (2.5 L) and filtered again. The washed polymer was dried at 60°C in a forced-air oven gave 18.8 g of a solid (0.36 g/g yield, IPS=18.4)
  • Example 8 - Copolymer of Diallylamine and Acrylamide
  • A solution of diallylammonium chloride (73.53 g of 68% aqueous solution), methylenebisacrylamide (2.93 g, 0.019 mol), 2,2'-azobis(2-amidinopropane) dihydrochloride (0.5 g) and water (27 mL) was heated at 70°C under a nitrogen atmosphere for 3 days. Water (100 mL) was added after the first 15 minutes of reaction. 2,2'-Azobis(2-amidinopropane)dihydrochloride (0.5 g) was added after 3 hours and 7 hours. The resulting material was filtered and washed with 2 M NaCl (400 mL) and water (2.5L). The washed polymer was dried at 60°C in a forced-air oven to give 18.8 g of a solid.
  • Example 9 - Copolymer of Diallylamine, Acrylamide and Methylenebisacrylamide
  • A solution of diallylammonium chloride (14.7 g of 68% aqueous), acrylamide (5.33 g), methylenebisacrylamide (2.31 g), MeOH (50 mL), and 2,2'-azobis(2-amidinopropane)dihydrochloride (0.07 g of an 18.8% solution of water) was heated at 65 °C under a nitrogen atmosphere for 20 hours. The resulting material was suspended in methanol (500 mL), stirred for 15 minutes and filtered. This methanol wash was repeated twice more. The washed polymer was suspended in water (500 mL) and this mixture was acidified with concentrated HCl to pH 2.4. Filtration, and drying at 60°C in a forced-air oven gave 9.8 g of a solid.
  • Example 10 - Copolymer of Diallylamine, a Functionalized Acrylic Ester and an Acrylic Ester Cross-linking Monomer
  • A solution of diallylammonium chloride (14.7 g of 68% aqueous), 2-hydroxyethylmethacrylate (9.76 g), ethyleneglycol dimethacrylate (2.97 g), MeOH (25 mL), and 2,2'-azobis(2-amidinopropane) dihydrochloride (0.07 g of an 18.8% aqueous solution) was heated at 65°C under a nitrogen atmosphere for 20 hours. The resulting material was suspended in methanol (500 mL), stirred for 15 minutes and filtered. The polymer was similarly washed three times with water (500 mL). This methanol wash and filtration were repeated twice more. The washed polymer was suspended in water (500 mL) and this mixture was acidified with concentrated HCl to pH 2.1. Filtration and drying at 60°C in a forced-air oven gave 13.9 g of a solid.
  • Example 11 - Copolymer of Diallylamine, a Functionalized Acrylic Ester and an Acrylic Ester Cross-linking Monomer
  • A solution of diallylammonium chloride (22.06 g of a 68% aqueous solution), tetrahydrofurfuryl methacrylate (18.72 g), ethyleneglycol dimethacrylate (4.36 g) and 2,2'-azobis(2-amidinopropane) dihydrochloride (2.03 g of an 18.8% aqueous solution) was heated at 65°C under a nitrogen atmosphere for 24 hours. The resulting material was suspended in methanol (300 mL), stirred 15 minutes and filtered. This methanol wash and filtration was repeated twice more. The polymer was similarly washed three times with water (500mL). The material was suspended in water (500 mL) and this mixture was acidified with concentrated HCl to pH 2.0. Filtration, and drying at 60°C in a forced-air oven gave 19.9 g of a solid.
  • Example 12 - Copolymer of Diallylamine and Glycidylmethacrylate
  • A solution of diallylammoniium chloride (29.42 g of a 68% aqueous solution), glycidylmethacrylate (2.13 g), MeOH (25 mL), and 2,2'-azobis(2-amidinopropane) dihydrochloride (1.18 g of an 18.8% aqueous solution) was heated at 65°C under a nitrogen atmosphere for 12 hours. After cooling to room temperature, methanol (25 mL) was added and the pH of the solution was adjusted to 10 with the addition of 50% aqueous NaOH, and allowed to stir at room temperature. The reaction solution turned to a solid mass after about 2 hours, and was allowed to stand for 22 hours. The resulting gel, was suspended in MeOH (300 mL), stirred and filtered. This methanol wash and filtration were repeated twice more. The polymer was then suspended in water (1 L). Concentrated HCl was added to this suspension until pH 2.0 and stirred 0.5 hours. Filtration and drying in a forced-air oven at 60°C gave 6.0 g of a solid.
  • Example 13 - Copolymer of Allylamine, Diallylamine, Triallylamine and a Bis(diallylamino)alkylene salt
  • A solution of allylammonium chloride (25.0 g of a 60% aqueous solution), diallylammonium chloride (66.81 g of a 67% aqueous solution), triallylammonium chloride (40.87 g of a 68% aqueous solution), 1,6-bis(diallylmethylammoniium) hexane dibromide (5.0 g), and 2,2'-azobis(2-amidinopropane) dihydrochloride (4.28 g of a 20% aqueous solution), was heated at 55 °C under a nitrogen atmosphere for 18 hours and at 80°C for 2 hours. After cooling to room temperature, the gel was suspended in MeOH (500 mL), stirred 15 minutes and filtered. This method was repeated. The polymer was suspended in water (1.0 L) and stirred at least 15 minutes and filtered. After drying in a 60°C forced-air oven, 31.9 g of solid was isolated.
  • Example 14 - Copolymer of Allylamine and Diallylamine
  • A solution of allylammonium chloride (54.71 g of a 57% aqueous solution), diallylammonium chloride (132.96 g of a 67% aqueous solution), and 2,2'-azobis(2-amidinopropane)dihydrochloride (6.01 g of a 20% aqueous solution), was heated at 55 °C under a nitrogen atmosphere for 36 hours. Another portion of 2,2'-azobis(2-amidinopropane)dihydrochloride (6.01 g of a 20% aqueous solution) was added after the first 18 hours. After cooling to room temperature, the solution was added slowly to IPA (3 L), and the precipitate after decanting the IPA layer, was washed with IPA (3 L) and filtered. The precipitate was dried in a forced-air oven at 60°C to afford 106.9 g of a solid.
  • Example 15 - Copolymer of Allylamine, Diallylamine and a Bis(diallylamino) alkylene
  • A solution of allylammonium chloride (27.36 g of a 57% aqueous solution), diallylammonium chloride (66.48 g of a 67% aqueous solution), 1,6-bis(diallylmethylammonium) hexane dibromide (10.0 g), and 2,2'-Azobis(2-amidinopropane) dihydrochloride (3.01 g of a 20% aqueous solution(, was heated at 55°C under a nitrogen atmosphere for 36 hours. Another portion of 2,2'-Azobis(2-amidinopropane) dihydrochloride (3.01 g of a 20% aqueous solution) was added after the first 18 hours. A gel formed after about 24 hours of heating. After cooling to room temperature, this material was washed with MeOH (500 mL) and filtered three times, as described above. The polymer was then suspended and washed with water (2.5 L). After filtration, the wet material was dried in a forced-air oven at 60°C to afford 24.8 g of a solid.
  • Example 16 - In Vivo Testing
  • Male Golden Syrian Hamsters were group housed in shoe box cages and acclimated for approximately 1 week in our animal facility. Animals were fed rodent chow (brown color) and water ad libitum. The hamsters were then transferred to metabolism cages and housed individually. Following a 24 hour fast (water ad libitum), animals were presented a casein-based purified diet (white color) with 10% fat added plus the drug to be evaluated. Fecal material was collected from 9 hours after the casein-based diet was presented for 39 additional hours. The white fecal pellets (drug-containing casein-based diet) were lyophilized and ground to a homogeneous powder. One gram of the ground fecal pellet was extracted in a solution consisting of methanol and 500 mM aqueous NaOH (4:1; v/v) at 100°C and 1500 psi for 15 minutes. A 500 µL aliquot of the extract was evaporated and reconstituted in 1500 µL bovine calf serum:0.9% saline (1:1) and analyzed enzymatically, utilizing a test kit for bile acids (Sigma Chemical Co., St. Louis, MO) for bile acid concentration.
    Polymer Dose (% in feed) Fecal Bile Acids (µmol/g)
    None None 1.34
    Example 6 .10 2.19
    Example 6 .15 3.44
    Example 6 .20 3.72
    Example 6 .25 3.48
    Cholestyramine 0.30 3.00
    Colestipol 0.30 2.81
    This example shows that crosslinked polydiallylamine is a highly potent bile acid sequestrant, with in vivo activity greater than current commercial products, Colestipol and Cholestyramine.
  • EQUIVALENTS
  • Those skilled in the art will know, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. These and all other equivalents are intended to be encompassed by the following claims.

Claims (10)

  1. Use of a polymer for the manufacture of a medicament for removing bile salts from a patient, the polymer comprising a polydiallylamine polymer and salts thereof, said polymer being substantially free of alkylated amine monomers.
  2. The use according to claim 1, wherein the polymer is free of alkylated amine monomers.
  3. A polydiallylamine polymer and salts thereof, substantially free of alkylated amine monomers for use in medical treatment or therapy.
  4. The polydiallylamine polymer and salts thereof according to claim 3, wherein the polymer is a bile acid sequestrant.
  5. The use of a polymer of claim 3 or claim 4, wherein the polymer is crosslinked by means of a multifunctional crosslinking agent, said agent being present in an amount of from 0.5-50% by weight, based upon the combined weight of monomer and crosslinking agent.
  6. The polymer of one of claims 3 to 5, wherein said crosslinking agent is present in an amount from 2.5-20% by weight, based upon the combined weight of monomer and crosslinking agent.
  7. The polymer of one of claims 3 to 6, wherein said crosslinking agent comprises either (a) epichlorohydrin, or (b) a bis(diallylammonium)dialkylene ion.
  8. The polymer of one of claims 3 to 7, wherein either (a) the polymer is a homopolymer, or (b) the polymer is a copolymer.
  9. The polymer of claim 8(b), wherein the copolymer comprises the monomers diallylamine, allylamine, and triallylamine, or the copolymer comprises the monomers diallylamine and allylamine.
  10. The use of claim 1 or claim 2, in which the polymer comprises the polymer of any one of claims 3 to 9.
EP98957370A 1997-11-05 1998-10-26 Unsubstituted polydiallylamine for treating hypercholesterolemia Expired - Lifetime EP1028717B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/964,536 US6083497A (en) 1997-11-05 1997-11-05 Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US964536 1997-11-05
PCT/US1998/022605 WO1999022721A2 (en) 1997-11-05 1998-10-26 Unsubstituted polydiallylamine for treating hypercholesterolemia

Publications (2)

Publication Number Publication Date
EP1028717A2 EP1028717A2 (en) 2000-08-23
EP1028717B1 true EP1028717B1 (en) 2003-03-26

Family

ID=25508662

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98957370A Expired - Lifetime EP1028717B1 (en) 1997-11-05 1998-10-26 Unsubstituted polydiallylamine for treating hypercholesterolemia

Country Status (20)

Country Link
US (6) US6083497A (en)
EP (1) EP1028717B1 (en)
JP (1) JP4649039B2 (en)
KR (1) KR20010031822A (en)
CN (1) CN1278180A (en)
AR (1) AR013742A1 (en)
AT (1) ATE235236T1 (en)
AU (1) AU746876B2 (en)
BR (1) BR9813961A (en)
CA (1) CA2309027C (en)
DE (1) DE69812681T2 (en)
ES (1) ES2196625T3 (en)
HU (1) HUP0004279A3 (en)
IL (1) IL135858A0 (en)
NO (1) NO20002172L (en)
NZ (1) NZ504216A (en)
PL (1) PL340296A1 (en)
TW (1) TW453878B (en)
WO (1) WO1999022721A2 (en)
ZA (1) ZA989673B (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US6268392B1 (en) * 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6083497A (en) * 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
PL364888A1 (en) * 1999-10-19 2004-12-27 Geltex Pharmaceuticals, Inc. Direct compression polymer tablet core
GB9927088D0 (en) 1999-11-17 2000-01-12 Secr Defence Use of poly(diallylamine) polymers
FI113613B (en) * 1999-11-24 2004-05-31 Eritocap Oy Food compositions and methods for their preparation
WO2002085379A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for improving vascular access in patients with vascular shunts
EP1923064B1 (en) 2001-04-18 2017-06-28 Genzyme Corporation Use of amine polymer for lowering serum glucose
WO2002085380A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid
WO2002085377A1 (en) * 2001-04-18 2002-10-31 Genzyme Corporation Method for lowering serum glucose
CA2444028A1 (en) * 2001-04-18 2002-10-31 Genzyme Corporation Methods of treating syndrome x with aliphatic polyamines
CN1290515C (en) * 2001-04-18 2006-12-20 基酶有限公司 Method for treating gout and reducing serum uric a cid
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
CA2456732C (en) 2001-08-07 2012-10-30 Galephar M/F Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor
US7223887B2 (en) * 2001-12-18 2007-05-29 The University Of British Columbia Multivalent cationic lipids and methods of using same in the production of lipid particles
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
MXPA05000050A (en) * 2002-07-03 2005-04-08 Esperion Therapeutics Inc Compositions comprising panthetine for the treatment of dyslipidemia.
US6565896B1 (en) * 2002-07-03 2003-05-20 Vitacost.Com, Inc. Cholesterol treatment formulation
AT411463B (en) 2002-09-03 2004-01-26 Dsm Fine Chem Austria Gmbh High yield production of alkylated nitrogen containing crosslinked polymer gels, e.g. epichlorohydrin crosslinked poly allylamine hydrochloride, comprises washing with methanol, sodium chloride and water
WO2004037274A1 (en) * 2002-10-22 2004-05-06 Genzyme Corporation Amine polymers for promoting bone formation
AT412473B (en) 2003-01-15 2005-03-25 Dsm Fine Chem Austria Gmbh METHOD FOR THE CONTINUOUS DRYING OF N- BZW. AMINO, AMMONIUM OR SPIROBICYCLIC AMMONIUM GROUPS OF POLYMERS
US7264813B2 (en) * 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
US20050106267A1 (en) * 2003-10-20 2005-05-19 Framework Therapeutics, Llc Zeolite molecular sieves for the removal of toxins
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
JP2008533272A (en) * 2005-03-16 2008-08-21 ユーエスヴィー リミテッド Improved method for the preparation of crosslinked polyallylamine polymers
US20070014866A1 (en) * 2005-07-15 2007-01-18 Curt Hendrix Composition for improving the efficacy and reducing the side effects of omega 3 fatty acids, fish oils and cardiovascular and diabetic treatments
US8986669B2 (en) * 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
AR056499A1 (en) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd COMPOUNDS
WO2008023213A1 (en) * 2005-09-12 2008-02-28 Council Of Scientific And Industrial Research Bile acid sequestrant and process for preparation thereof
AU2012205214B2 (en) * 2005-09-15 2015-05-21 Genzyme Corporation Formulation for Amine Polymers
DK1924246T3 (en) 2005-09-15 2016-01-18 Genzyme Corp PORTION LETTER DEFINITION OF amine polymers
JP2009536246A (en) * 2006-05-05 2009-10-08 ゲンズイメ コーポレーション Amine condensation polymers as phosphate scavengers.
WO2008011047A2 (en) * 2006-07-18 2008-01-24 Genzyme Corporation Amine dendrimers
BRPI0717545A2 (en) 2006-09-29 2013-10-22 Gezyme Corp PHARMACEUTICAL COMPOSITION, METHOD FOR TREATING A DISEASE, AMIDE POLYMER, POLYMER NETWORK, AND METHOD FOR PREPARING AN AMIDE POLYMER
US20080118572A1 (en) * 2006-10-10 2008-05-22 Harold Richard Hellstrom Methods and compositions for reducing the risk of adverse cardiovascular events associated with the administration of artificial blood
JP2010513271A (en) 2006-12-14 2010-04-30 ゲンズイメ コーポレーション Amide-amine polymer composition
JP2010519298A (en) * 2007-02-23 2010-06-03 ゲンズイメ コーポレーション Amine polymer composition
US20090326013A1 (en) * 2007-03-01 2009-12-31 Curt Hendrix Isomers of inositol niacinate and uses thereof
EP2131820A1 (en) * 2007-03-08 2009-12-16 Genzyme Corporation Sulfone polymer compositions
EP2152277A1 (en) * 2007-04-27 2010-02-17 Genzyme Corporation Amido-amine dendrimer compositions
JP2011506449A (en) * 2007-12-14 2011-03-03 ジェンザイム コーポレーション Coating pharmaceutical composition
WO2009154747A1 (en) * 2008-06-20 2009-12-23 Genzyme Corporation Pharmaceutical compositions
WO2010014541A2 (en) * 2008-07-28 2010-02-04 Alnara Pharmaceuticals, Inc. Compositions and methods for treatment of hypercholesterolemia
DE102009040089A1 (en) * 2009-09-04 2011-07-21 Beiersdorf AG, 20253 Preparations with water-insoluble polymeric amines for the reduction of body odor
CN102906159B (en) * 2010-02-24 2017-09-26 瑞立普萨公司 Amine polymer as bile acid sequestrant
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CN102993348B (en) * 2011-09-09 2014-11-12 北大方正集团有限公司 Sevelamer niacin, preparation method and application
CN103012789B (en) * 2011-09-23 2015-02-25 北大方正集团有限公司 Preparation method of niacin sevelamer
US20140243281A1 (en) 2011-10-28 2014-08-28 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
CN103030713A (en) * 2012-12-21 2013-04-10 江南大学 Preparation method of low-molecular-weight glucan-niacin polymer with hypolipidemic activity
MA41202A (en) 2014-12-18 2017-10-24 Genzyme Corp CROSS-LINKED POLYDIALLYMINE COPOLYMERS FOR THE TREATMENT OF TYPE 2 DIABETES
US10245284B2 (en) 2015-08-19 2019-04-02 Alpex Pharma S.A. Granular composition for oral administration
WO2024040380A1 (en) * 2022-08-22 2024-02-29 中美华世通生物医药科技(武汉)股份有限公司 Ammonium salt polymer, method for preparing same, and use thereof as bile acid chelating agent

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR593106A (en) 1924-02-15 1925-08-17 Rhenania Ver Chemischer Fab Ag Highly concentrated chlorine production process
US2926161A (en) * 1958-03-10 1960-02-23 Peninsular Chem Res Inc Linear homopolymers of diallyl amines
GB860303A (en) 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
US3288770A (en) * 1962-12-14 1966-11-29 Peninsular Chem Res Inc Water soluble quaternary ammonium polymers
SE337383B (en) 1965-01-05 1971-08-09 Yoshitomi Pharmaceutical
FR1498459A (en) 1965-07-30 1968-01-08
GB1175516A (en) 1966-04-15 1969-12-23 Science Union & Cie New Phenyl-Aminopropane Derivatives and Preparations Containing them
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4058552A (en) 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
DE2003430C3 (en) 1969-01-31 1978-12-07 Laboratorien Fournier Gmbh, 6600 Saarbruecken p-Benzoylphenoxyisobutyric acid esters, their preparation and pharmaceuticals containing them
FI52570C (en) 1969-04-16 1977-10-10 Sumitomo Chemical Co Process for producing the cholesterol or lipoid content of the blood using phenoxyaliphatic carboxylic acid compounds and ester compounds.
GB1268082A (en) 1969-08-08 1972-03-22 Orsymonde Improvements in or relating to bis-(carboxy-alkylene-thio)-decanes
AT296986B (en) 1969-08-13 1972-03-10 Merz & Co Process for the production of new α-halophenoxy-isobutyroyl-β-nicotinoyl glycols
US3840504A (en) * 1970-01-26 1974-10-08 Hercules Inc Reaction products of epihalohydrin and polymers of diallylamine and their use in paper
US3700623A (en) * 1970-04-22 1972-10-24 Hercules Inc Reaction products of epihalohydrin and polymers of diallylamine and their use in paper
US3833531A (en) * 1970-04-22 1974-09-03 Hercules Inc Reaction products of epihalohydrin and polymers of diallylamine and salts thereof and their use in paper
DE2149070C3 (en) 1971-10-01 1978-03-23 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarboxylic acid derivatives and their salts, processes for their production and pharmaceuticals
DE2230383C3 (en) 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarboxylic acid derivatives and processes for making the same
US3948973A (en) 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
AU472260B2 (en) * 1972-12-22 1976-05-20 Commonwealth Scientific + Industrial Research Organisation And Ici Australia Limited A process OF POLYMERISATION OF ALLYL AMINES
US3966694A (en) * 1973-02-21 1976-06-29 Hercules Incorporated Cationic water soluble polymeric reaction product of poly(diallylamine)-epihalohydrin and nitrogen compound
DE2308826C3 (en) 1973-02-22 1980-03-27 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren Phenoxyalkanecarboxylic acid esters of oxyalkyl theophyllines, process for their preparation and pharmaceuticals
US4027009A (en) * 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
FR2244511B1 (en) 1973-07-05 1977-07-15 Roussel Uclaf
CH617417A5 (en) 1973-12-27 1980-05-30 Siegfried Ag
JPS5612114B2 (en) 1974-06-07 1981-03-18
JPS5157793A (en) * 1974-11-15 1976-05-20 Nitto Boseki Co Ltd JIARIRUAMIN JUDOTAINO JUGOTAIO SEIZOSURU HOHO
US4121986A (en) * 1975-05-07 1978-10-24 Ici Australia Limited Process for the polymerization of polyallylamines in the presence of a mineral acid solution
US4049813A (en) 1976-07-15 1977-09-20 Sandoz, Inc. Substituted isoxazolo pyridinones
AU509755B2 (en) * 1976-12-13 1980-05-22 Commonwealth Scientific And Industrial Research Organisation Basic ion exchange resins
US4298715A (en) * 1978-03-01 1981-11-03 Monsanto Company Polyamine/epihalohydrin reaction products
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
GR69216B (en) 1979-06-15 1982-05-07 Merck & Co Inc
JPS5618611A (en) * 1979-07-24 1981-02-21 Nippon Kayaku Co Ltd Production of diallyldialkylammonium chloride
US4230626A (en) 1979-07-30 1980-10-28 G. D. Searle & Co. 25-Halocholest-5-ene-3β,22-diols and esters thereof
JPS5651992A (en) 1979-10-03 1981-05-09 Sankyo Co Ltd Preparation of physiologically active substance ml-236b
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
AU548996B2 (en) 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
MX7065E (en) 1980-06-06 1987-04-10 Sankyo Co A MICROBIOLOGICAL PROCEDURE FOR PREPARING DERIVATIVES OF ML-236B
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
IE52006B1 (en) * 1980-12-12 1987-05-13 Smith & Nephew Ass Polymers of diallyl ammonium monomers pharmaceutical compositions thereof
US4452957A (en) * 1982-08-11 1984-06-05 National Starch And Chemical Corporation Process for the production of homo- and co-polymers of quaternary ammonium monomers
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
CH660852A5 (en) * 1982-11-23 1987-05-29 Aligena Ag DYNAMIC MEMBRANES THAT ARE THIN THIN POLYMER LAYERS ON POROUS, POLYMER CARRIER MATERIALS.
JPS6088018A (en) * 1983-10-21 1985-05-17 Nitto Boseki Co Ltd Production of copolymer of monoallylamine with diallylamine derivative
US4604217A (en) * 1984-09-13 1986-08-05 Hercules Incorporated Gelled aqueous compositions
JPS6322056A (en) 1986-04-30 1988-01-29 サンド・アクチエンゲゼルシヤフト Manufacture of olefinic compound
EP0245003A3 (en) 1986-05-05 1989-07-19 Merck & Co. Inc. Antihypercholesterolemic compounds
US4759923A (en) * 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
US4946963A (en) 1987-11-13 1990-08-07 The University Of North Carolina At Chapel Hill Compounds for the control of hyperlipidemia using N-substituted isoxazolidine-3,5-diones
DK33789A (en) 1988-01-27 1989-07-28 May & Baker Ltd ISOQUINOLINONER
US5055613A (en) 1988-02-18 1991-10-08 G. D. Searle & Co. Metabolites of pentanedioic acid derivatives
US4853437A (en) * 1988-03-04 1989-08-01 Hercules Incorporated Water- and caustic-insoluble, inswellable, fibrous, particulate crosslinked polymer
WO1990000897A1 (en) 1988-07-27 1990-02-08 University Of North Carolina At Chapel Hill Method for the control of hyperlipidemia
US5200482A (en) * 1988-09-12 1993-04-06 The Dow Chemical Company Process for the production of high molecular weight copolymers of diallyl ammonium monomers and acrylamide monomers in solution
JPH02237988A (en) 1988-11-18 1990-09-20 Nissan Chem Ind Ltd Isooxazolopyridine-based mevalonolactone
GB8829835D0 (en) * 1988-12-21 1989-02-15 Smith Kline French Lab Compounds
FR2642065B1 (en) 1989-01-24 1991-05-24 Lipha DERIVATIVES OF ALCOHANIC BENZOCYCLOALCENYL DIHYDROXY ACIDS, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM
CA2007641A1 (en) 1989-02-01 1990-08-01 Donald S. Karanewsky Combination of squalene synthetase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination
CA2016467A1 (en) 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
US4937259A (en) 1989-06-09 1990-06-26 Merck & Co., Inc. Antihypercholesterolemic compounds
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
US5316765A (en) 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
DE3929913A1 (en) 1989-09-08 1991-04-04 Hoechst Ag 4-HYDROXYTETRAHYDROPYRAN-2-ONE AND THE CORRESPONDING DIHYDROXYCARBONSAEUREDERIVATES, SALTS AND ESTERS, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT, PHARMACEUTICAL PREPARATES AND PREPARED PRODUCTS
JPH0627137B2 (en) 1989-09-22 1994-04-13 第一工業製薬株式会社 Method for polymerizing diallylamine and its derivatives
US5128366A (en) 1990-07-05 1992-07-07 Shinogi & Co., Ltd. Pyrrole derivatives
IE914179A1 (en) 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
US5134155A (en) 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
DE59307535D1 (en) * 1992-07-22 1997-11-20 Hoechst Ag Polyvinylamine derivatives which have hydrophilic centers, processes for their preparation and the use of the compounds as medicaments, active substance carriers and food additives
ATE146193T1 (en) * 1992-07-22 1996-12-15 Hoechst Ag CROSS-LINKED, NITROGEN-CONTAINING VINYL COPOLYMERS, METHOD FOR THE PRODUCTION THEREOF AND THE USE OF THESE COMPOUNDS
KR950703016A (en) * 1992-08-20 1995-08-23 미리암디. 메코나헤어 CROSSLINKED POLYMERIC AMMONIUM SALTS
US5556619A (en) * 1992-08-20 1996-09-17 The Du Pont Merck Pharmaceutical Company Crosslinked polymeric ammonium salts
US5310949A (en) 1992-09-02 1994-05-10 Merck & Co., Inc. Cholesterol lowering compounds
US5274155A (en) 1992-12-07 1993-12-28 E. R. Squibb & Sons, Inc. Intramolecular arbuzov process for the preparation of intermediates useful in the preparation of phosphorus containing HMG-COA reductase inhibitors
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5624963A (en) * 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5703188A (en) * 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
JP3498853B2 (en) 1993-09-27 2004-02-23 小野薬品工業株式会社 Biphenyl derivative
ZA95390B (en) * 1994-01-18 1996-07-18 Du Pont Crosslinked polymeric ammonium salts
US5414068A (en) * 1994-01-24 1995-05-09 Rohm And Haas Company Crosslinked anion exchange particles and method for producing the particles
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
JP3006748B2 (en) 1994-09-06 2000-02-07 宇部興産株式会社 Process for producing optically active 7-substituted pyridyl-3,5-dihydroxy-hept-6-enoic acid ester derivatives
US5942297A (en) 1996-03-07 1999-08-24 Cryovac, Inc. By-product absorbers for oxygen scavenging systems
US6203785B1 (en) * 1996-12-30 2001-03-20 Geltex Pharmaceuticals, Inc. Poly(diallylamine)-based bile acid sequestrants
RU2247579C2 (en) 1997-03-11 2005-03-10 Джи. Ди. Сирл Энд Ко. Combined treatment using benzothiepins inhibiting transport of bile acid in jejunum and inhibitors of hmg-coa-reductase
GB2329334A (en) 1997-09-18 1999-03-24 Reckitt & Colmann Prod Ltd Cholesterol-lowering agents
US6726905B1 (en) * 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
US6083497A (en) * 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers

Also Published As

Publication number Publication date
US6248318B1 (en) 2001-06-19
AR013742A1 (en) 2001-01-10
TW453878B (en) 2001-09-11
WO1999022721A2 (en) 1999-05-14
NZ504216A (en) 2002-11-26
US6083497A (en) 2000-07-04
NO20002172L (en) 2000-07-04
ATE235236T1 (en) 2003-04-15
US20100266526A1 (en) 2010-10-21
DE69812681D1 (en) 2003-04-30
US7638524B2 (en) 2009-12-29
CA2309027C (en) 2007-10-02
EP1028717A2 (en) 2000-08-23
HUP0004279A2 (en) 2002-03-28
US6264938B1 (en) 2001-07-24
JP2001521890A (en) 2001-11-13
CN1278180A (en) 2000-12-27
WO1999022721A3 (en) 1999-08-05
JP4649039B2 (en) 2011-03-09
AU746876B2 (en) 2002-05-02
ES2196625T3 (en) 2003-12-16
US20020155091A1 (en) 2002-10-24
PL340296A1 (en) 2001-01-29
HUP0004279A3 (en) 2002-04-29
ZA989673B (en) 1999-05-11
DE69812681T2 (en) 2004-04-29
IL135858A0 (en) 2001-05-20
NO20002172D0 (en) 2000-04-27
BR9813961A (en) 2000-09-26
AU1364699A (en) 1999-05-24
CA2309027A1 (en) 1999-05-14
KR20010031822A (en) 2001-04-16
US6365186B1 (en) 2002-04-02

Similar Documents

Publication Publication Date Title
EP1028717B1 (en) Unsubstituted polydiallylamine for treating hypercholesterolemia
CA2349620C (en) Use of aliphatic polyamines for reducing oxalate
US6203785B1 (en) Poly(diallylamine)-based bile acid sequestrants
US6566407B2 (en) Method for reducing oxalate
US6726905B1 (en) Poly (diallylamines)-based phosphate binders
CA2294036C (en) Polyallylamine polymers for treating hypercholesterolemia
EP1404349B1 (en) Fat-binding polymers
US20020182168A1 (en) Method for reducing copper levels and treating copper toxicosis
WO2000069445A1 (en) Combination therapy for treating hypercholesterolemia
MXPA00004329A (en) Unsubstituted polydiallylamine for treating hypercholesterolemia
WO2000069446A1 (en) Combination therapy for treating hypercholesterolemia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000531

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010906

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/00 A, 7A 61P 3/00 B

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GELTEX PHARMACEUTICALS, INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DHAL, PRADEEP, K.

Inventor name: PETERSEN, JOHN, S.

Inventor name: HOLMES-FARLEY, STEPHEN, RANDALL

Inventor name: HUVAL, CHAD, CORI

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030326

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030326

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

BECA Be: change of holder's address

Owner name: *GENZYME CORP.ONE KENDALL SQUARE, CAMBRIDGE, MASSA

Effective date: 20030326

BECH Be: change of holder

Owner name: *GENZYME CORP.

Effective date: 20030326

REF Corresponds to:

Ref document number: 69812681

Country of ref document: DE

Date of ref document: 20030430

Kind code of ref document: P

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030626

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030626

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030626

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: GENZYME CORPORATION

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: GENZYME CORPORATION

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: GENZYME CORPORATION

Free format text: GELTEX PHARMACEUTICALS, INC.#153 SECOND AVENUE#WALTHAM, MA 02451 (US) -TRANSFER TO- GENZYME CORPORATION#ONE KENDALL SQUARE#CAMBRIDGE (MA 02139) (US)

Ref country code: CH

Ref legal event code: NV

Representative=s name: PATENTANWAELTE FELDMANN & PARTNER AG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031026

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031026

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031031

NLS Nl: assignments of ep-patents

Owner name: GENZYME CORPORATION

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2196625

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20031230

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 69812681

Country of ref document: DE

Representative=s name: MAI DOERR BESIER EUROPEAN PATENT ATTORNEYS - E, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 69812681

Country of ref document: DE

Representative=s name: MAI DOERR BESIER PATENTANWAELTE, DE

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1027746

Country of ref document: HK

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20170918

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20170913

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20171018

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20171013

Year of fee payment: 20

Ref country code: NL

Payment date: 20171016

Year of fee payment: 20

Ref country code: ES

Payment date: 20171102

Year of fee payment: 20

Ref country code: IE

Payment date: 20171010

Year of fee payment: 20

Ref country code: GB

Payment date: 20171025

Year of fee payment: 20

Ref country code: IT

Payment date: 20171024

Year of fee payment: 20

Ref country code: AT

Payment date: 20170926

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69812681

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

Ref country code: NL

Ref legal event code: MK

Effective date: 20181025

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20181025

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20181026

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 235236

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181026

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20181026

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20181025

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20201201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20181027